Start of procedure: Extension of marketing authorisation (22 May 2026 - 25 June 2026)
Human medicines European public assessment report (EPAR): Alprolix, eftrenonacog alfa, Date of authorisation: 12/05/2016, Revision: 12, Status: Authorised
Seventeenth Industry Standing Group (ISG) meeting, Online, from 29 June 2026, 09:30 (CEST) to 29 June 2026, 13:10 (CEST)
17th Industry Standing Group (ISG) meeting, Online, from 29 June 2026, 09:30 (CEST) to 29 June 2026, 13:10 (CEST)
New product information wording: extracts from PRAC recommendations on signals adopted at the 8-11 June 2026 PRAC
PRAC recommendations on signals adopted at the 8-11 June 2026 PRAC meeting
Human medicines European public assessment report (EPAR): Rexatilux, ranibizumab, Date of authorisation: 19/06/2026, Status: Authorised
EMA/PE/0000234516
EMA/PE/0000230610
EMA/PE/0000238858